FOLFIRI super( registered ) and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms

Background: Over 50% of colorectal cancer (CRC) patients develop metastases. The aim of this study was to evaluate efficacy and tolerance of first-line FOLFIRI registered + bevacizumab (B) treatment for metastatic CRC, and to assess genetic polymorphisms as potential markers. Methods: Adult patients...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	BMC research notes 2014-01, Vol.7 (1), p.260-260
Hauptverfasser:	Becouarn, Yves, Cany, Laurent, Pulido, Marina, Beyssac, Richard, Texereau, Patrick, Le Morvan, Valerie, Bechade, Dominique, Brunet, Rene, Aitouferoukh, Sofiane, Lalet, Caroline, Mathoulin-Pelissier, Simone, Fonck, Marianne, Robert, Jacques
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!